Earnings
Home›Earnings›Results›McKesson beats expectations in fiscal 2026, raises gui…
McKesson beats expectations in fiscal 2026, raises guidance
The company reported $96.3 billion in fourth-quarter revenue, and launched a $2.25 billion accelerated share repurchase program.
McKesson closed fiscal 2026 with strong results and increased its outlook, extending momentum in its pharmaceutical distribution and specialty care businesses, according to MarketBeat Ratings.
In its fourth quarter ended March 31, McKesson reported revenue of $96.3 billion, up 6% year over year, while earnings per diluted share rose to $13.71, supported by higher prescription volumes in its North American Pharmaceutical operations and continued expansion in Oncology and Multispecialty. Adjusted diluted EPS rose 16% to $11.69, above analysts expectations.
For the full fiscal year, McKesson delivered consolidated revenue of $403.4 billion, up 12%, with earnings per share of $38.38. Adjusted EPS reached $39.11, an 18% increase that exceeded the company’s previously announced long-range growth targets.
McKesson also highlighted cash generation and capital returns, producing $3.4 billion of cash flow from operations in the quarter and about $3.2 billion in free cash flow after $185 million of capital expenditures. The company launched a $2.25 billion accelerated share-repurchase program and received board approval for a $5 billion increase to its total repurchase authorization, lifting buyback capacity to $7.7 billion as of April, and it raised forward guidance including fiscal 2027 adjusted EPS of $43.8 to $44.6.